Bank Julius Baer & Co
CBIO

Bank Julius Baer & Co’s Crescent Biopharma CBIO Stock Holding History

Bank Julius Baer & Co’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50
Closed -$7K – 667
2021
Q4 		$7K Hold
50
– – ﹤0.01% 798
2021
Q3 		$11K Buy
+50
New +$10.6K ﹤0.01% 773

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank Julius Baer & Co's CBIO Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Crescent Biopharma (CBIO) in Q1 2022, closing a stake of 50 shares — an estimated $7K sold.

Bank Julius Baer & Co first reported a position in CBIO in Q3 2021 and held it in 2 quarters. The position peaked at $11K in Q3 2021. 43 funds tracked by Wall St. Rank hold CBIO as of Q1 2022.

  • Bank Julius Baer & Co reported no remaining Crescent Biopharma position as of Q1 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 50 Crescent Biopharma shares in Q1 2022, an estimated $7K.
  • Bank Julius Baer & Co first reported a position in Crescent Biopharma in Q3 2021 and held it in 2 quarters.
  • Bank Julius Baer & Co's Crescent Biopharma position peaked at $11K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.